IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
1993 in South Ko rea as Brosporin. Takeda is not de vel op ing the prod uct in the US. In Oc to ber 2006,
Takeda brought a le gal ac tion to re in state a US pat ent cov er ing meth ods for man u fac tur ing cephem
compounds.
TAKESULIN (cefsulodin), an in ject able cephalosporin an ti bi otic de vel oped in-house by Takeda, was first
launched by li censee Ciba in France in 1980. It was launched in 1981 in Ja pan. Novartis and Takeda
co-mar ket the prod uct in Ja pan and cer tain other mar kets out side North Amer ica, while in some mar kets,
Novartis sells the prod uct in de pend ently. It has been filed in the US by TAP, Takeda’s joint ven ture with
Abbott (USA), but has never been launched there, al though Abbott launched it as Cefmonil in Can ada in
1986. The TAP joint ven ture con cluded in May 2008 and Takeda re ceived rights to this pro gram. Takeda
mar kets the drug in France and has launched it in In do ne sia, Ma lay sia, the Phil ip pines and Thai land. In
Ger many and Aus tria, the drug is mar keted by Takeda Pharma. Novartis now mar kets the prod uct in a
num ber of Eu ro pean coun tries, as well as in Israel, Saudi Arabia and Thailand.
TMR (vac cine, live, at ten u ated mea sles, ru bella) is a freeze-dried, live, at ten u ated mea sles and ru bella
com bi na tion vac cine, launched in Ja pan in Jan u ary 2006 for the pre ven tion of mea sles and rubella.
OTC Prod ucts
Takeda’s main prod uct in the Con sumer Health busi ness is the Alinamin range of vi ta min and tonic prod -
ucts. Other prod ucts in the di vi sion in clude cold rem e dies, con sti pa tion med i cines and vi ta min C prod -
ucts. The Con sumer Healthcare busi ness ac counts for about 4.6% of Takeda’s rev e nues, but it posted a
slight in crease in sales from Yen58.7 bil lion to Yen61.8 bil lion in the year to March 2008.
Takeda pre sum ably still sees its Con sumer Health di vi sion as core to its con tin u ing busi ness, al though
there was no men tion of it in the lat est five-year man age ment plan. How ever there are at pres ent no
plans to di vest it as has hap pened with other non-phar ma ceu ti cal businesses.
Ma jor prod ucts in clude:
ACTAGE musculoskeletal prod ucts. Actage AN, a prod uct for musculoskeletal prob lems and for vi ta min
B1 supplementation was launched in March 2003.
ALINAMIN vi ta min and tonic prod ucts. Alinamin is Takeda’s best-sell ing OTC brand. The range in cludes
Alinamin A25 (vi ta min B1 tab lets), Alinamin EX (a vi ta min E-for ti fied vi ta min B1, B6 and B12 com -
pound), Alinamin V, a 50ml vi ta min B com plex health tonic drink, launched in 1987, Alinamin Dy -
namic, a 100ml tonic drink, launched in 1996, and New Alinamin A, which con tains more vi ta min B6
and B12 than the orig i nal prod uct, launched in 1999. In the year to March 31 2008, sales of Alinamin
more than dou bled to Yen35 bil lion (from Yen14.6 bil lion) and for Alinamin Drink to Yen32 bil lion (from
Yen12.1 bil lion the pre vi ous year) and pro jected by an a lysts at Mor gan Stan ley to drop and re main at
Yen60 bil lion and Yen15 bil lion re spec tively from fis cal 2008 through 2012 (ending March 2013).
BENZA (acetylsalicylic acid/ascor bic acid), a line of cough and cold treat ments, first launched in 1966.
Prod ucts in clude Benza Ace and Benza De con ges tant. Benza AL Spray for rhi ni tis was launched in
Ja pan in 1998. Benza Block Cough Syrup was launched in 1999. In 2003, Takeda an nounced ces sa -
tion of pro duc tion and mar ket ing of some of its phenypropanolamine-con tain ing Benza prod ucts; no ta bly
the cold rem edy Benza Block SP (ibuprofen/phenylpropanolamine). With drawal from the mar ket fol -
lowed warn ings from the Jap a nese Health, Wel fare and La bor de part ment that
phenypropanolamine-con tain ing prod ucts might be linked to ce re bral hem or rhagic ad verse ef fects. In
the year to March 31 2008, sales of Benza in creased to Yen10 bil lion (from Yen7.7 bil lion the pre vi ous
year) and pro jected by an a lysts at Mor gan Stan ley to drop and re main at Yen8.5 bil lion from fiscal 2008
through 2012 (ending March 2013).
© 2009 IMS Health In cor po rated or its af fil i ates Page 53